The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

Jennifer Chan, MD, MPH, discussed outcomes of treating neuroendocrine tumors (NETs) with cabozantinib depending on whether they were pancreatic NETs or extrapancreatic NETs.

However, previous studies have focused on differentiating PSPN from other pancreatic tumors. Few studies have employed contrast-enhanced CT (CECT) radiomics to predict the invasiveness of PSPN. The ...

Patients treated for advanced neuroendocrine tumors (NETs) are at risk of disease progression after existing treatments, and the current options are often dependent on particular disease factors that ...

Woese Institute for Genomic Biology, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States Pancreatic neuroendocrine ... PAC-1 enhances PNET cell death in cell culture and ...

The gut microbiome has emerged as a potential factor in cancer pathogenesis, but its role in non-functioning pituitary neuroendocrine tumors (NF-PitNETs) remains unclear. This study aimed to elucidate ...

Pancreatic cancer is on the rise in the United States, but there's another, less common type called pancreatic neuroendocrine tumors (PNET). It's important to know the difference, because these two ...

The U.S. Food & Drug Administration has granted approval for a new drug to treat pancreatic neuroendocrine tumors, also called PNET or PanNET. “I am delighted that patients with pancreatic ...